COMP <GO>
NGEN vs MGNX // EV/EBITDA & P/E VALUATION
NervGen Pharma Corp. (NASDAQ) VS. MacroGenics Inc. (NASDAQ) • 15-METRIC TALLY: NGEN 2
— MGNX 0
■ METRIC PARITY
LAST: $1.37 (-4.86%) • MKT CAP: $155.0M
valuation
—
LAST: $2.40 (+0.84%) • MKT CAP: $151.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NGEN VS. MGNX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NGEN | MGNX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -48.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 0.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -0.30% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.7 | 33.0 | +1.72 | NGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $155.0M | $151.6M | $3.4M | NGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NGEN REV | MGNX REV | NGEN GROSS % | MGNX GROSS % | NGEN FCF | MGNX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $149.5M | — | 98.0% | — | -$83.0M |
| FY 2024 | — | $150.0M | — | 98.0% | — | -$72.1M |
| FY 2023 | — | $58.7M | — | — | — | -$78.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NGEN // BETA —
MGNX // BETA —